Tilfrinib

Research use only, not for human use.

Tilfrinib is an effective and selective inhibitor of breast tumor kinase (IC50: 3.15 nM), which displays anti-proliferative activity.

Tilfrinib is an effective and selective inhibitor of breast tumor kinase (IC50: 3.15 nM), which displays anti-proliferative activity.(In Vitro):Tilfrinib is against MCF7, HS-578/T, and BT-549 cells with GI50 values of 0.99, 1.02 and 1.58 μM.

Tilfrinib (20 μM; 36 h) shows inhibition of PTK6, and decreases the ETV4 WT-induced expression of CXCL1 or CXCL8 in UM-UC-3 cells and expression of VEGFA or MMP9 in TANs.Tilfrinib (compound 4f) shows good anti-proliferative activity against MCF7, HS-578/T and BT-549 cells with GI50 values of 0.99, 1.02 and 1.58 μM. Western Blot Analysis Cell Line:UM-UC-3 cells (stably expressing FLAG-ETV4 WT or Y392F)Concentration:20 μM Incubation Time:36 h Result:Reduced ETV4 WT-induced expression of CXCL1 or CXCL8 in UM-UC-3 cells and expression of VEGFA or MMP9 in TANs by inhibiting PTK6.

——

——

Tyrosine Kinase

BTK

Nav1.7 channel

——

——

1600515-49-8

275.311

C17H13N3O

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (454.05 mM)

Oc1cccc(Nc2ccnc3[nH]c4ccccc4c23)c1

——

(-20℃)

With Ice Pack

≥ 2 years